Reports in the late 2010’s tell us that the cannabis plant contains around 110 cannabinoids, though 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been the been the main thing that medical researchers have been looking into.
THC is the one that offers the psychoactive effects, such as cognitive impairments, psychosis, dysphoria, and anxiety, whereas CBD is non-intoxicating and has anti-inflammatory, analgesic, and antipsychotic properties, and can counter the effects of THC, whether they were wanted or not.
A considerable amount of patients who suffer from multiple sclerosis (PwMS) have begun to, or are thinking about making use of cannabis to deal with their symptoms.
Other studies have shown that there is a huge amount of acceptance of cannabis within the MS community, anywhere between 20 to 60% of MS sufferers making use of this plant, and 50–90% would be inclined to use it if it were legalised, and further information was available.
A forever increasing number of US states have, over time, incorporated laws to legalise cannabis for medical reasons, and there were changes in US state law as of December 2020.
We at CBDzine do hope that the world will see one day see the sense of all this evidence, and finally legalise this plant.